RA Cap­i­tal-backed non-vi­ral gene ther­a­py start­up Sum­ma­tion Bio to shut down

As a string of new gene ther­a­py star­tups aims to cre­ate treat­ments with­out the go-to shut­tling method of an AAV virus, and as mul­ti­ple gene edit­ing biotechs look to do the same, one such start­up is com­ing to a close.

Sum­ma­tion Bio, backed by at least $24 mil­lion in Se­ries A funds, is “ter­mi­nat­ing op­er­a­tions” next month, per an em­ploy­ee’s LinkedIn pro­file up­date. (Ac­cord­ing to their LinkedIn pro­file, an em­ploy­ee said the com­pa­ny raised $60 mil­lion in the round.) An­oth­er em­ploy­ee took to the net­work­ing site last week to say the cir­cum­stances were “in­sur­mount­able,” not­ing that “de­spite all-out ef­fort and er­ror-free ex­e­cu­tion, the sci­ence, this time, was elu­sive.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.